Given that our prognostic model partially incorporates monocyte differentiation, it is reasonable to hypothesize that ATRX mutations in LMS may induce monocytes to adopt an immunosuppressive state by impairing mast cell function within the TIME, thereby influencing the tumor’s immune response and overall prognosis. This evidence concerns the gene ATRX and neoplasm.